Spots Global Cancer Trial Database for A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome
Official Title: Phase I/II Trial of Subcutaneous Decitabine Maximizing Genomic Demethylation in Patients With Myelodysplastic Syndrome.
Study ID: NCT00282399
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study was to determine which of the doses of decitabine maximizes genomic demethylation in patients with Myelodysplastic Syndrome (MDS).
Detailed Description: Phase I: The purpose of this study was to determine which of the subcutaneous doses of decitabine administered twice daily for 5 days maximizes genomic demethylation in patients with MDS Phase II: To evaluate hematological responses at the dose selected in the Phase I portion of the study. Note: This study was planned as Phase 1/2 study but only the Phase 1 part was conducted due to a change in product development strategy
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Arizona Cancer Center, Tucson, Arizona, United States
H Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Albert Einstein College of Medicine, Bronx, New York, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
